Literature DB >> 31036436

Compassionate use of unauthorized drugs: Legal regulations and ethical challenges.

Jan Borysowski1, Andrzej Górski2.   

Abstract

Compassionate use (also referred to as expanded access) is therapeutic use of unauthorized drugs outside of clinical trials. The objective of this review is to discuss practical aspects of the current legal regulations concerning compassionate use that have been introduced in the European Union, the USA (both the Food and Drug Administration regulations and Right-to-try laws), Canada and Australia. We also present main ethical challenges associated with use of unauthorized drugs such as possible difficulties with obtaining informed consent and fair patient selection. Moreover, we discuss guidelines, especially those contained in the Declaration of Helsinki, which may aid doctors in the ethical conduct of compassionate treatments.
Copyright © 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Compassionate use; Expanded access; Investigational drug; Unauthorized drug

Year:  2019        PMID: 31036436     DOI: 10.1016/j.ejim.2019.04.008

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  9 in total

1.  International Country-Level Trends, Factors, and Disparities in Compassionate Use Access to Unlicensed Products for Patients With Serious Medical Conditions.

Authors:  Paul Aliu; Séverine Sarp; Ramona Reichenbach; Sigrid Behr; Paige Fitzsimmons; Mansurahmad Shamlajee; Surya Prakash Kola; Samantha Nunes Radimerski; Emil Scosyrev
Journal:  JAMA Health Forum       Date:  2022-04-15

Review 2.  Topical application of bacteriophages for treatment of wound infections.

Authors:  Rachel Yoon Kyung Chang; Sandra Morales; Yuko Okamoto; Hak-Kim Chan
Journal:  Transl Res       Date:  2020-03-19       Impact factor: 7.012

3.  Experiences of caregivers of children with spinal muscular atrophy participating in the expanded access program for nusinersen: a longitudinal qualitative study.

Authors:  Petra Kiefer; Janbernd Kirschner; Astrid Pechmann; Thorsten Langer
Journal:  Orphanet J Rare Dis       Date:  2020-07-29       Impact factor: 4.123

4.  Current regulatory approaches for accessing potential COVID-19 therapies.

Authors:  Vesa Halimi; Armond Daci; Simona Stojanovska; Irina Panovska-Stavridis; Milena Stevanovic; Venko Filipce; Aleksandra Grozdanova
Journal:  J Pharm Policy Pract       Date:  2020-05-16

5.  Structural violence and the need for compassionate use of methadone in Mexico.

Authors:  Martha Romero-Mendoza; Ingris Peláez-Ballestas; Ariagor Manuel Almanza-Avendaño; Emilia Figueroa
Journal:  BMC Public Health       Date:  2022-03-29       Impact factor: 3.295

6.  A Thorough Synthesis of Phage Therapy Unit Activity in Poland-Its History, Milestones and International Recognition.

Authors:  Maciej Żaczek; Andrzej Górski; Beata Weber-Dąbrowska; Sławomir Letkiewicz; Wojciech Fortuna; Paweł Rogóż; Edyta Pasternak; Ryszard Międzybrodzki
Journal:  Viruses       Date:  2022-05-28       Impact factor: 5.818

7.  Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021.

Authors:  Hideki Maeda; Marika Uchida; Mikiko Kusano; Katsura Tsukamoto; Moeka Yamanoi
Journal:  Clin Pharmacol Ther       Date:  2022-06-07       Impact factor: 6.903

8.  Understanding the challenges and ethical aspects of compassionate use of drugs in emergency situations.

Authors:  Pardeep Kumar Goyal; Roli Mathur; Bikash Medhi
Journal:  Indian J Pharmacol       Date:  2020-08-04       Impact factor: 1.200

9.  Ethics framework for treatment use of investigational drugs.

Authors:  Jan Borysowski; Andrzej Górski
Journal:  BMC Med Ethics       Date:  2020-11-18       Impact factor: 2.652

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.